US FDA tells generic drug makers how to use 'controlled correspondence'
This article was originally published in SRA
The US Food and Drug Administration has for the first time attempted to formally define its so-called "controlled correspondence" process which generic drug companies have used for a number of years now to submit questions to the agency on specific elements of drug development1-3.
You may also be interested in...
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.